Bristol-Myers enters option agreement to acquire Danish firm

Bristol-Myers enters option agreement to acquire Danish firm


US pharma major Bristol-Myers Squibb has entered into an exclusive option agreement to buy Denmark-based…

BiotechnologyBristol-Myers SquibbGalecto BiotechMergers & AcquisitionsRespiratory and PulmonaryTD139

UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

B-MS ties knot with Duke University on R&D


Bristol-Myers Squibb has forged a partnership with Duke University in the USA that will see the academic…

Bristol-Myers SquibbCardio-vascularGeneralHomeLysophosphatidic acid 1 (LPA1)MetabolicsOncologyPfizerPharmaceuticalRespiratory and PulmonarySanofi

Bristol-Myers Squibb to pay up to $475 million to acquire Amira, entering fibrotic disease area


US drug major Bristol-Myers Squibb (NYSE: BMY) has signed a definitive agreement to acquire privately…

Amira PharmaceuticalsBristol-Myers SquibbMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

Back to top